π VC round data is live in beta, check it out!
SPIMACO - ADDWAEIH Valuation Multiples
Discover revenue and EBITDA valuation multiples for SPIMACO - ADDWAEIH and similar public comparables like Keqian Biology, SanBio, Gen İlaç, MedinCell and more.
SPIMACO - ADDWAEIH Overview
About SPIMACO - ADDWAEIH
Saudi Pharmaceutical Industries & Medical Appliances Corp is involved in the manufacturing of basic chemical substances and products; medicines for human use, including cosmetics; pharmaceutical production and wholesale and retail of medicines and related products; development and marketing of medicinal and pharmaceutical products; research and development in medical science activities; operating and maintaining the healthcare facilities and any investments in related industries. The segments of the company are Pharmaceutical Manufacturing, Trading and Distribution services, and Healthcare Services, out of which the company derives maximum revenue from the Pharmaceutical Manufacturing segment. Its geographical segments are Saudi Arabia, Egypt, the Middle East, Morocco, and Algeria.
Founded
1986
HQ
Employees
N/A
Website
Financials (LTM)
EV
$1B
SPIMACO - ADDWAEIH Financials
SPIMACO - ADDWAEIH reported last 12-month revenue of $468M and EBITDA of $100M.
In the same LTM period, SPIMACO - ADDWAEIH generated $100M in EBITDA and $50M in net income.
Revenue (LTM)
SPIMACO - ADDWAEIH P&L
In the most recent fiscal year, SPIMACO - ADDWAEIH reported revenue of $449M and EBITDA of $67M.
SPIMACO - ADDWAEIH expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $468M | XXX | $449M | XXX | XXX | XXX |
| Gross Profit | β | XXX | $223M | XXX | XXX | XXX |
| Gross Margin | β | XXX | 50% | XXX | XXX | XXX |
| EBITDA | $100M | XXX | $67M | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 15% | XXX | XXX | XXX |
| EBIT Margin | 16% | XXX | 9% | XXX | XXX | XXX |
| Net Profit | $50M | XXX | $7M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | 1% | XXX | XXX | XXX |
| Net Debt | β | β | $368M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
SPIMACO - ADDWAEIH Stock Performance
SPIMACO - ADDWAEIH has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
SPIMACO - ADDWAEIH's stock price is $8.63.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | 0.0% | XXX | XXX | XXX | $0.05 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSPIMACO - ADDWAEIH Valuation Multiples
SPIMACO - ADDWAEIH trades at 2.8x EV/Revenue multiple, and 13.2x EV/EBITDA.
EV / Revenue (LTM)
SPIMACO - ADDWAEIH Financial Valuation Multiples
As of April 18, 2026, SPIMACO - ADDWAEIH has market cap of $1B and EV of $1B.
Equity research analysts estimate SPIMACO - ADDWAEIH's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
SPIMACO - ADDWAEIH has a P/E ratio of 20.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 2.8x | XXX | 2.9x | XXX | XXX | XXX |
| EV/EBITDA | 13.2x | XXX | 19.5x | XXX | XXX | XXX |
| EV/EBIT | 18.0x | XXX | 31.3x | XXX | XXX | XXX |
| EV/Gross Profit | β | XXX | 5.9x | XXX | XXX | XXX |
| P/E | 20.6x | XXX | 157.2x | XXX | XXX | XXX |
| EV/FCF | β | XXX | (11.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified SPIMACO - ADDWAEIH Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
SPIMACO - ADDWAEIH Margins & Growth Rates
SPIMACO - ADDWAEIH's revenue in the last 12 month grew by 10%.
SPIMACO - ADDWAEIH's rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
SPIMACO - ADDWAEIH's rule of X is 46% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
SPIMACO - ADDWAEIH Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | 44% | XXX | XXX | XXX |
| Rule of 40 | β | XXX | 31% | XXX | XXX | XXX |
| Bessemer Rule of X | β | XXX | 46% | XXX | XXX | XXX |
| S&M Expenses to Revenue | β | XXX | 6% | XXX | XXX | XXX |
| G&A Expenses to Revenue | β | XXX | 6% | XXX | XXX | XXX |
| R&D Expenses to Revenue | β | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | β | XXX | 40% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
SPIMACO - ADDWAEIH Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| SPIMACO - ADDWAEIH | XXX | XXX | XXX | XXX | XXX | XXX |
| Keqian Biology | XXX | XXX | XXX | XXX | XXX | XXX |
| SanBio | XXX | XXX | XXX | XXX | XXX | XXX |
| Gen İlaç | XXX | XXX | XXX | XXX | XXX | XXX |
| MedinCell | XXX | XXX | XXX | XXX | XXX | XXX |
| CytomX Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SPIMACO - ADDWAEIH M&A Activity
SPIMACO - ADDWAEIH acquired XXX companies to date.
Last acquisition by SPIMACO - ADDWAEIH was on XXXXXXXX, XXXXX. SPIMACO - ADDWAEIH acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by SPIMACO - ADDWAEIH
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSPIMACO - ADDWAEIH Investment Activity
SPIMACO - ADDWAEIH invested in XXX companies to date.
SPIMACO - ADDWAEIH made its latest investment on XXXXXXXX, XXXXX. SPIMACO - ADDWAEIH invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by SPIMACO - ADDWAEIH
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout SPIMACO - ADDWAEIH
| When was SPIMACO - ADDWAEIH founded? | SPIMACO - ADDWAEIH was founded in 1986. |
| Where is SPIMACO - ADDWAEIH headquartered? | SPIMACO - ADDWAEIH is headquartered in Saudi Arabia. |
| Is SPIMACO - ADDWAEIH publicly listed? | Yes, SPIMACO - ADDWAEIH is a public company listed on Tadawul. |
| What is the stock symbol of SPIMACO - ADDWAEIH? | SPIMACO - ADDWAEIH trades under 2070 ticker. |
| Who are competitors of SPIMACO - ADDWAEIH? | SPIMACO - ADDWAEIH main competitors are Keqian Biology, SanBio, Gen İlaç, MedinCell. |
| What is the current market cap of SPIMACO - ADDWAEIH? | SPIMACO - ADDWAEIH's current market cap is $1B. |
| What is the current revenue of SPIMACO - ADDWAEIH? | SPIMACO - ADDWAEIH's last 12 months revenue is $468M. |
| What is the current revenue growth of SPIMACO - ADDWAEIH? | SPIMACO - ADDWAEIH revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of SPIMACO - ADDWAEIH? | Current revenue multiple of SPIMACO - ADDWAEIH is 2.8x. |
| Is SPIMACO - ADDWAEIH profitable? | Yes, SPIMACO - ADDWAEIH is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of SPIMACO - ADDWAEIH? | SPIMACO - ADDWAEIH's last 12 months EBITDA is $100M. |
| What is SPIMACO - ADDWAEIH's EBITDA margin? | SPIMACO - ADDWAEIH's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of SPIMACO - ADDWAEIH? | Current EBITDA multiple of SPIMACO - ADDWAEIH is 13.2x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.